Business Context and Reporting Period
This Form 8-K was filed by Illumina, Inc. on December 3, 2012, reporting an event that occurred on November 27, 2012. The filing addresses regulatory compliance regarding a proposed corporate acquisition.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory filing event rather than financial performance.
Material Changes
The material change reported is the initiation of the regulatory review process for a proposed acquisition. On November 27, 2012, Illumina submitted a notification filing with the U.S. Department of Justice and the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Outlook, Risks, and Unusual Items
- Acquisition Target: The filing concerns the proposed acquisition of Complete Genomics, Inc.
- Regulatory Status: The transaction is subject to antitrust review by federal authorities.
- Management Commentary: No additional commentary, guidance, or risk factors beyond the notification of the filing are included in this document.
Investor Verification Checklist
- Verify the current status of the Hart-Scott-Rodino waiting period for the Complete Genomics acquisition.
- Confirm whether the U.S. Department of Justice or FTC has issued any challenges or requests for additional information.
- Review subsequent filings for the final closing date and terms of the acquisition.